Top Industry Leaders in the Rumination Syndrome Market
Latest Rumination Syndrome Companies Updates:
Biofeedback Innovations, Inc.: Launched the NeuroSky MindBody® System in December 2023, featuring biofeedback-guided exercises for regulating physiological responses and potentially mitigating rumination symptoms.
Interactive Health Inc.: Introduced the Reset™ app in October 2023, offering CBT-based modules and mindfulness exercises for managing anxiety and stress, which can contribute to rumination.
Akili Interactive Labs, Inc.: Received FDA clearance for their EndeavorRx™ video game in June 2023, a therapeutic digital game targeting attention-deficit/hyperactivity disorder (ADHD) which can sometimes co-occur with Rumination Syndrome.
Springtide Therapeutics Inc.: Developed the ST-001 investigational drug for treating rumination syndrome, currently undergoing Phase 2 clinical trials.
The International Rumination Syndrome Foundation: Provides educational resources and support groups for individuals affected by Rumination Syndrome, fostering awareness and research initiatives.
List of Rumination Syndrome Key companies in the market:
- Pfizer Inc.
- Valent Pharmaceuticals
- Medtronic
- Astra Zeneca
- Eisai Co. Ltd.
- Takeda Pharmaceuticals
- Allergan Plc.
- Novo Nordisk A/S